Company news

Telix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notice of General Meeting

October 29, 2026

Telix Reports Third Quarter 2026 Financial Performance

October 20, 2026

Telix Reports Third Quarter 2026 Financial Performance

October 20, 2026

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

October 14, 2026

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

October 8, 2026

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara (floretyrosine F 18)

October 6, 2026

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

October 6, 2026

Notification of cessation of securities - TLX

October 4, 2026

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

September 29, 2026

FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging

September 29, 2026

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

September 20, 2026

Telix and ITM Join Forces to Create Radiopharma Powerhouse

September 20, 2026

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

September 13, 2026

FDA Approves Telix Brain Cancer Imaging Drug Pixclara

September 13, 2026

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

September 1, 2026

Telix Appoints David Gill as Chair

August 31, 2026

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

August 19, 2026

Telix HY26 Results Presentation

August 19, 2026

Telix HY26 Results Announcement

August 19, 2026

Telix HY26 Appendix 4D and Interim Report

August 19, 2026

Telix to Host R&D Day in New York City on September 22, 2026

August 5, 2026

Telix H1 2026 Results: Investor Webcast Notification

July 30, 2026

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

July 21, 2026

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

July 20, 2026

Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress

July 20, 2026

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

July 20, 2026

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

July 16, 2026

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

July 15, 2026

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

July 15, 2026

Notification of cessation of securities - TLX

July 10, 2026

FDA Alignment to Advance ProstACT Global Phase 3 Trial

July 1, 2026

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

June 22, 2026

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

June 1, 2026

Telix and United Imaging Announce Strategic Theranostics Collaboration

June 2, 2026

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

May 18, 2026

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

May 15, 2026

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

May 4, 2026

TLX101-Px (Pixlumi®) MAA Accepted in Europe

April 30, 2026

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

April 29, 2026

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

April 27, 2026

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

April 21, 2026

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

April 14, 2026

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

April 14, 2026

Telix Successfully Prices Upsized US$600M Convertible Bonds

April 14, 2026

Telix Investor Presentation April 2026

April 14, 2026

Telix Refinances Convertible Bonds

April 14, 2026

Telix and Regeneron Announce Strategic Radiopharma Collaboration

April 13, 2026

Regeneron and Telix Announce Strategic Radiopharma Collaboration

April 13, 2026

Telix and Regeneron Announce Radiopharma Collaboration

April 12, 2026

Older news releases →

Calls

Decks

The 5 newest of 56 decks. Every deck is listed under its year.